Skip to Content

Join the 'Reslizumab' group to help and get support from people like you.

Reslizumab News

New Biologic Drug Tackles Hard-to-Control Asthma

Posted 7 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – A new injectable drug reduces flare-ups in patients with severe asthma that is not controlled by steroid inhalers alone, two new trials show. The drug, benralizumab, is a biologic that works by killing white blood cells called eosinophils. These are present in large numbers in such patients, and they have been linked to severe asthma. If approved by the U.S. Food and Drug Administration, benralizumab would join two similar drugs – mepolizumab (Nucala) and reslizumab (Cinqair) – in fighting hard-to-control asthma, the researchers said. "We can offer patients who frequently require courses of oral corticosteroids and have a certain level of eosinophils [an allergy-related cell easily measured in the blood] a very effective treatment," said study author Dr. J. Mark FitzGerald. He is a professor of respiratory health at the University of British Columbia in ... Read more

Related support groups: Asthma, Asthma - Maintenance, Asthma - Acute, Nucala, Allergic Asthma, Mepolizumab, Cinqair, Reslizumab

Cinqair Approved for Severe Asthma

Posted 23 Mar 2016 by Drugs.com

WEDNESDAY, March 23, 2016 – Cinqair (reslizumab) has been approved by the U.S. Food and Drug Administration to treat severe asthma among adults 18 and older. The drug is to be used in combination with other medications, the agency noted. In a Wednesday news release, the agency said that more than 22 million people in the United States have asthma, which leads to more than 400,000 hospitalizations annually. Cinqair, given by injection every four weeks, is designed to reduce severe asthma attacks by reducing blood levels of eosinophils, a white blood cell that contributes to asthma, the FDA said. In clinical studies involving an unspecified number of severe asthma sufferers, people who took Cinqair had fewer severe attacks than those who took a placebo, and a longer time to the first attack, the agency said. Users of Cinqair, a lab-developed "interleukin-5 antagonist monoclonal ... Read more

Related support groups: Asthma, Asthma - Maintenance, Cinqair, Reslizumab

FDA Approves Cinqair (reslizumab) to Treat Severe Asthma

Posted 23 Mar 2016 by Drugs.com

March 23, 2016 – The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening. According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year. “Health care providers and their patients with severe a ... Read more

Related support groups: Asthma, Asthma - Maintenance, Cinqair, Reslizumab

Ask a Question

Further Information

Related Condition Support Groups

Asthma

Related Drug Support Groups

Cinqair

Reslizumab Patient Information at Drugs.com